title: Chemotherapy-induced Cardiotoxicity.
abstract: Breast cancer represents the most frequent form of neoplasia in women worldwide, being responsible of 1.6% of annual deaths. Therefore, it is a major public health issue and research in this field should be a priority. Chemoterapics drugs are extremly potent tools, which alone or in association to radiotherapy, increase survival and lower the reccurrence rate of cancer, but their use can be limited by cardiotoxicity. Cardiotoxicity can appear early or late after therapy, and may vary from subclinical myocardial dysfunction to irreversible heart failure. Currently, cardiac dysfunction induced by chemotherapy is diagnosed through classical echocardiographic parameters. However, these cannot detect subtle, early changes of cardiac structure and function. Consequently, description of new methods, which could detect cardiac dysfunction in an early stage, becomes essential for detecting the group of patients at risk for irreversible heart failure and for monitoring the treatment.
authors.affiliation: Emergency University Hospital, Bucharest, Romania ; "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
authors.forename: Maria
authors.initials: M
authors.lastname: Florescu
authors.forename: Mircea
authors.initials: M
authors.lastname: Cinteza
authors.forename: Dragos
authors.initials: D
authors.lastname: Vinereanu
keywords: cardiotoxicity; chemotherapy; non-invasive methods
references.citation: Heart. 2006 Aug;92(8):1102-8
references.pmid: 16387826
references.citation: Int J Cardiol. 2008 Aug 29;128(3):311-5
references.pmid: 18374999
references.citation: Nat Med. 2002 May;8(5):459-65
references.pmid: 11984589
references.citation: Circulation. 2006 Dec 5;114(23):2474-81
references.pmid: 17101852
references.citation: Expert Opin Drug Saf. 2006 Nov;5(6):791-809
references.pmid: 17044806
references.citation: Curr Cardiol Rev. 2011 Nov;7(4):234-44
references.pmid: 22758624
references.citation: J Clin Oncol. 2005 Nov 1;23(31):7820-6
references.pmid: 16258084
references.citation: Nat Clin Pract Oncol. 2008 Jun;5(6):324-35
references.pmid: 18364726
references.citation: Cancer Treat Rev. 2004 Apr;30(2):181-91
references.pmid: 15023436
references.citation: Eur Heart J. 2007 Nov;28(22):2698
references.pmid: 17567624
references.citation: Nat Med. 2007 Jan;13(1):13-4; author reply 15-6
references.pmid: 17206117
references.citation: JAMA. 1991 Sep 25;266(12):1672-7
references.pmid: 1886191
references.citation: Ann Intern Med. 1979 Nov;91(5):710-7
references.pmid: 496103
references.citation: Am J Cardiol. 1996 Apr 15;77(10):843-50
references.pmid: 8623737
references.citation: Circulation. 2010 Feb 9;121(5):675-83
references.pmid: 20100968
references.citation: Environ Health Perspect. 2001 Mar;109 Suppl 1:27-34
references.pmid: 11250803
references.citation: J Clin Oncol. 1984 Feb;2(2):112-7
references.pmid: 6699662
references.citation: Target Oncol. 2009 Apr;4(2):89-97
references.pmid: 19418112
references.citation: Circulation. 2005 Nov 15;112(20):3149-56
references.pmid: 16286606
references.citation: Eur J Echocardiogr. 2006 Mar;7(2):141-6
references.pmid: 15941672
references.citation: Oncologist. 2009 Jan;14(1):1-11
references.pmid: 19147689
references.citation: J Huazhong Univ Sci Technolog Med Sci. 2009 Jun;29(3):391-4
references.pmid: 19513629
references.citation: Am J Med. 1987 Jun;82(6):1109-18
references.pmid: 3605130
references.citation: J Am Coll Cardiol. 2010 Jan 19;55(3):213-20
references.pmid: 20117401
references.citation: Nat Med. 2006 Aug;12(8):908-16
references.pmid: 16862153
references.citation: Drug Saf. 2008;31(6):459-67
references.pmid: 18484781
references.citation: Cardiovasc Hematol Agents Med Chem. 2006 Jan;4(1):1-5
references.pmid: 16529545
references.citation: Circulation. 2004 Jun 29;109(25):3122-31
references.pmid: 15226229
references.citation: Circulation. 2004 Jun 8;109(22):2749-54
references.pmid: 15148277
references.citation: Semin Oncol. 2006 Jun;33(3 Suppl 8):S15-21
references.pmid: 16781285
references.citation: Cancer Treat Rev. 2009 Apr;35(2):175-84
references.pmid: 19013720
references.citation: Ann Oncol. 2010 Oct;21 Suppl 7:vii173-9
references.pmid: 20943611
references.citation: J Am Coll Cardiol. 2006 Dec 5;48(11):2258-62
references.pmid: 17161256
references.citation: Am J Cardiol. 2011 May 1;107(9):1375-80
references.pmid: 21371685
references.citation: Tex Heart Inst J. 2011;38(3):253-6
references.pmid: 21720463
references.citation: Circulation. 2002 Aug 27;106(9):e40; author reply e40
references.pmid: 12196350
references.citation: J Am Coll Cardiol. 2006 Oct 3;48(7):1475-97
references.pmid: 17010819
references.citation: Am J Hematol. 2008 Nov;83(11):862-70
references.pmid: 18819092
references.citation: Minerva Cardioangiol. 2007 Dec;55(6):711-20
references.pmid: 18091640
references.citation: Am J Clin Pathol. 2008 Nov;130(5):688-95
references.pmid: 18854260
references.citation: Am Heart J. 2009 Aug;158(2):294-301
references.pmid: 19619708
references.citation: Curr Cardiol Rev. 2011 Nov;7(4):245-9
references.pmid: 22758625
references.citation: J Natl Cancer Inst. 2010 Jan 6;102(1):14-25
references.pmid: 20007921
references.citation: J Clin Oncol. 2002 Mar 1;20(5):1215-21
references.pmid: 11870163
references.citation: Cancer. 2003 Jun 1;97(11):2869-79
references.pmid: 12767102
references.citation: BMC Cancer. 2010 Jun 29;10:337
references.pmid: 20587042
references.citation: J Nucl Cardiol. 2012 Apr;19(2):377-88
references.pmid: 22351492
references.citation: J Am Coll Cardiol. 2009 Jun 16;53(24):2231-47
references.pmid: 19520246
references.citation: Ann Pharmacother. 2006 Dec;40(12):2278-9
references.pmid: 17105834
references.citation: Oncologist. 2007 Sep;12(9):1124-33
references.pmid: 17914082
references.citation: Clin Chem. 2005 Aug;51(8):1405-10
references.pmid: 15932966